Maximizing the adequacy of medication treatment in controlled trials and clinical practice: STAR(*)D measurement-based care

Clicks: 647
ID: 118735
2007
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #1 of 18 articles by views in neuropsychopharmacology : official publication of the american college of neuropsychopharmacology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Abstract
The success of well-developed protocols has been limited in real-world practice, where even effective strategies have not been sufficient to meet patient needs in routine clinical care owing to Axis I and III comorbidities. The Sequenced Treatment Alternatives to Relieve Depression (STAR(*)D) trial …
Reference Key
mh2007neuropsychopharmacologymaximizing Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Trivedi MH;Rush AJ;Gaynes BN;Stewart JW;Wisniewski SR;Warden D;Ritz L;Luther JF;Stegman D;Deveaugh-Geiss J;Howland R;;
Journal neuropsychopharmacology : official publication of the american college of neuropsychopharmacology
Year 2007
DOI
DOI not found
URL
Keywords

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

No comments yet. Be the first to comment on this article.